Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Gastric Cancer signs and symptoms include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Treatment includes surgery, chemotherapy, and radiation therapy.
The Gastric Cancer pipeline drugs market research report provides an analysis of the Gastric Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.
| Key Targets | Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1, Cells Expressing Claudin 18, Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Tubulin, Hepatocyte Growth Factor Receptor, CD3, Epidermal Growth Factor Receptor, Claudin 18, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2 |
| Key Mechanisms of Action | Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Claudin 18, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, CD3 Agonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor, Claudin 18 Inhibitor, Hepatocyte Growth Factor Receptor Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, and Fibroblast Growth Factor Receptor 2 Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Parenteral, Subcutaneous, Intravenous Drip, Intratumor, Intraperitoneal, Intravesical, Intramuscular, Intradermal, and Intralesional |
| Key Molecule Types | Monoclonal Antibody, Small Molecule, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Cell Therapy, Oncolytic Virus, Subunit Vaccine, Biologic, Synthetic Peptide, and Recombinant Protein |
| Key Companies | Bristol-Myers Squibb Co, Merck & Co Inc, CSPC Pharmaceutical Group Ltd, Incyte Corp, Shanghai Henlius Biotech Inc, Daiichi Sankyo Co Ltd, Innovent Biologics Inc, Jiangsu Hengrui Medicine Co Ltd, Pfizer Inc, Seagen Inc, Akeso Inc, Alphamab Oncology, and AstraZeneca Plc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Gastric Cancer Pipeline Drugs Market segmentation by Targets
Some of the targets of the Gastric Cancer pipeline drugs market are Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1, Cells Expressing Claudin 18, Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Tubulin, Hepatocyte Growth Factor Receptor, CD3, Epidermal Growth Factor Receptor, Claudin 18, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2 among others. In 2022, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 were the most dominant targets.
Gastric Cancer Pipeline Drugs Market Analysis by Targets, 2022 (%)
Buy the full report for more insights on key targets in the Gastric Cancer Pipeline Drugs Market, download a free report sample
Gastric Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action
The mechanisms of action of the Gastric Cancer pipeline drugs market are Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Claudin 18, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, CD3 Agonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor, Claudin 18 Inhibitor, Hepatocyte Growth Factor Receptor Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, and Fibroblast Growth Factor Receptor 2 Inhibitor among others. In 2022, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 were the most preferred MoA in the Gastric Cancer Pipeline Drugs market.
Gastric Cancer Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)
For more insights on mechanisms of action in the Gastric Cancer Pipeline Drugs Market buy full report or download a free report sample
Gastric Cancer Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the Gastric Cancer pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intravenous drip, intratumor, intraperitoneal, intravesical, intramuscular, intradermal, and intralesional among others. In 2022, the intravenous RoA was the mostly deployed in the Gastric Cancer Pipeline Drugs market.
Gastric Cancer Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)
Download a free sample for more insights on routes of administration in the Gastric Cancer Pipeline Drugs Market or buy the full report.
Gastric Cancer Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Gastric Cancer pipeline drugs market are Monoclonal Antibody, Small Molecule, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Cell Therapy, Oncolytic Virus, Subunit Vaccine, Biologic, Synthetic Peptide, and Recombinant Protein among others. In 2022, the most adopted molecule types in the Gastric Cancer Pipeline drugs market are monoclonal antibodies.
Gastric Cancer Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)
Buy the full report to know more about the molecules in the Gastric Cancer pipeline drugs market or download a free report sample
Gastric Cancer Pipeline Drugs Market – Competitive Landscape
Some of the leading companies in the Gastric Cancer pipeline drugs market are Bristol-Myers Squibb Co, Merck & Co Inc, CSPC Pharmaceutical Group Ltd, Incyte Corp, Shanghai Biotech Inc, Daiichi Sankyo Co Ltd, Innovent Biologics Inc, Jiangsu Hengrui Medicine Co Ltd, Pfizer Inc, Seagen Inc, Akeso Inc, Alphamab Oncology, and AstraZeneca Plc among others.
Gastric Cancer Pipeline Drugs Market by Leading Companies, 2022 (%)
To know more about the leading companies in the Gastric Cancer pipeline drugs market, buy the full report or download a free report sample
Key Segments Covered in this Report
Gastric Cancer Pipeline Drugs Targets Outlook (%, 2022)
- Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2
- Programmed Cell Death Protein 1
- Cells Expressing Claudin 18
- Receptor Tyrosine Protein Kinase ERBB 2
- Others
Gastric Cancer Pipeline Drugs Mechanisms of Action Outlook (%, 2022)
- Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2
- Programmed Cell Death Protein 1 Antagonist
- Cytotoxic To Cells Expressing Claudin 18
- Programmed Cell Death 1 Ligand 1 Inhibitor
- Others
Gastric Cancer Pipeline Drugs Routes of Administration Outlook (%, 2022)
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Intravenous Drip
- Others
Gastric Cancer Pipeline Drugs Molecule Types Outlook (%, 2022)
- Monoclonal Antibody
- Small Molecule
- Monoclonal Antibody Conjugated
- Gene-Modified Cell Therapy
- Fusion Protein
- Others
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
A28 Therapeutics Inc
Abbisko Cayman Limited
AbbVie Inc
Abclon Inc
Abion Inc
ABL Bio Inc
Abpro Corp
AbTis Co Ltd
Accurus Biosciences Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advenchen Laboratories LLC
Affimed GmbH
AffyImmune Therapeutics Inc
Agenus Inc
AIMM Therapeutics BV
Akeso Inc
Alkermes Plc
Alligator Bioscience AB
Alphamab Oncology
Alteogen Inc
AltruBio Inc
ALX Oncology Holdings Inc
Ambrx Biopharma Inc
amcure GmbH
Amgen Inc
Aminex Therapeutics Inc
Amunix Operating Inc
Andes Biotechnologies
Anhui Anke Biotechnology (Group) Co Ltd
Antengene Corp Ltd
Antikor Biopharma Ltd
Apollomics Inc
Apotex Inc
Aprea Therapeutics Inc
Aptacure Therapeutics Ltd
Arbele Ltd
Arcus Biosciences Inc
Argonaut Therapeutics Ltd
Arromax Pharmatech Co Ltd
Aryogen Pharmed Co
Asana BioSciences LLC
Ascelia Pharma AB
Ascenta Therapeutics Inc
Ascentage Pharma Group Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
AskAt Inc
AskGene Pharma Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Aurora BioPharma Inc
Avvinity Therapeutics Ltd
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing BGI-GBI Biotech Co Ltd
Beijing Biostar Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Konruns Pharmaceutical Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Beijing Syngentech Co Ltd
Beijing Wuhe Boao Pharmaceutical Technology Development Co Ltd
Beijng Immunoah Pharma Tech Co Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
Bicara Therapeutics Inc
Bicycle Therapeutics Plc
Bika Biotechnology Guanzhou Co Ltd
Bio-Synectics Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioEclipse Therapeutics Inc
BioIntegrator
BioInvent International AB
BioLineRx Ltd
BioMed Valley Discoveries Inc
Biomunex Pharmaceuticals
BioNTech SE
Biosion Inc
Biosplice Therapeutics Inc
BioSyngen Pte Ltd
Biotecnol Ltd
Biotheus Inc
Bioviz Technologies Pvt Ltd
BJ Bioscience Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
BreakBio Corp
BrickBio Inc
BridgeBio Pharma Inc
BrightGene Bio-Medical Technology Co Ltd
Bristol-Myers Squibb Co
Byondis BV
Calithera Biosciences Inc
CalyGene Biotechnology Inc
CanBas Co Ltd
Carisma Therapeutics Inc
Carrier (Beijing) Pharmaceutical Co Ltd
CARsgen Therapeutics Ltd
CAS-Lamvac Biotech Co Ltd
Catalent Inc
Catamaran Bio Inc
Cedilla Therapeutics
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellid Co Ltd
Cellivery Therapeutics Inc
Cellix Bio Pvt Ltd
Cello Therapeutics Inc
Celon Pharma SA
Celularity Inc
Cend Therapeutics Inc
Centrymed Pharmaceutical Inc
CGeneTech (Suzhou China) Co Ltd
Cheetah Cell Therapeutics Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
China Immunotech (Beijing) Biotechnology Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
Cloaked Therapeutics LLC
CMG Pharmaceutical Co Ltd
CNBX Pharmaceuticals Inc
Codiak BioSciences Inc
Coherent Biopharma
Conagen Inc
Convalife
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
CTG Pharma Ltd
Cue Biopharma Inc
Cumberland Pharmaceuticals Inc
Curegenix Inc
CureLab Oncology Inc
CureMeta LLC
Cytodyn Inc
CytoImmune Therapeutics Inc
CytomX Therapeutics Inc
D3 Bio Inc
Daiichi Sankyo Co Ltd
Defence Therapeutics Inc
Delta-Fly Pharma Inc
Diaccurate
DiNonA Inc
DM Bio Ltd
DNAtrix Inc
Dongguan Daxin Biotechnology Co Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Duo Oncology Inc
Dyadic International Inc
DynamiCure Biotechnology LLC
Eddingpharm Inc
Eden Biologics Inc
Eisai Co Ltd
Eli Lilly and Co
Ella Therapeutics Ltd
Ellipses Pharma Ltd
Elpiscience Biopharma Ltd
Elucida Oncology Inc
EOS Biosciences Inc
EpimAb Biotherapeutics Inc
EpiThany Inc
Epsilogen Ltd
ERYTECH Pharma SA
Etern BioPharma Co Ltd
eTheRNA Immunotherapies NV
Eutilex Co Ltd
Evopoint Bioscience Co Ltd
Excelmab Inc
Exeliom Biosciences SAS
Exelixis Inc
EXUMA Biotech Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
f5 Therapeutics Inc
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Frost Biologic Inc
Fusion Pharmaceuticals Inc
FutureGen Biopharm Technology Co Ltd
G+FLAS Life Sciences Inc
GAiA BioMedicine Inc
Galecto Inc
GC Biopharma Corp
Geneius Biotechnology Inc
Genentech USA Inc
GeneQuantum Healthcare Suzhou Co Ltd
GeneScience Pharmaceuticals Co Ltd
Genexine Inc
GenoImmune Therapeutics Biotechnology Co Ltd
Genome & Co
Genor BioPharma Co Ltd
GI Innovation Co Ltd
Gilead Sciences Inc
GLG Pharma SA
GlycoNex Inc
Glycotope GmbH
GO Therapeutics Inc
Good T Cells Inc
Green Cross LabCell Corp
Grid Therapeutics LLC
GSK plc
GT Biopharma Inc
Guangdong Yinzhu Pharmaceutical Technology Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Doublle Bioproduct Inc
Guangzhou Yinming Biomedical Technology Co Ltd
Haikou Qili Pharmaceutical Co Ltd
HaimBio Ltd
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou DAC Biotech Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
HebeCell Corp
Hebei Senlang Biotechnology Co Ltd
Helixmith Co Ltd
Hibercell Inc
HiFiBiO Therapeutics Inc
Highlight Therapeutics SL
Hillstream BioPharma Inc
HitGen Inc
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
Huadao Shanghai Biomedical Co Ltd
Huahui Anjian (Beijing) Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
I-Mab
Ideaya Biosciences Inc
Idience Co Ltd
IGM Biosciences Inc
ImCheck Therapeutics SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunisbio Co Ltd
ImmunityBio Inc
Immunocore Holdings Plc
Immunocore Limited
Immunomet Therapeutics Inc
Immunomic Therapeutics Inc
Immunotech Biopharm Ltd
ImmVirX Pty Ltd
Imugene Ltd
Incyte Corp
Inhibrx Inc
Innate Pharma SA
Inner Mongolia Qite Biotechnology (Group) Co Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Intocell Inc
Intra-Immusg Pvt Ltd
InxMed (Beijing) Co Ltd
Ipsen SA
Istari Oncology Inc
Ithax Pharmaceuticals Inc
JenKem Technology Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Jina Pharmaceuticals Inc
Jiuzhitang Co Ltd
Johnson & Johnson
Joint Biosciences Ltd
Jounce Therapeutics Inc
JW Pharmaceutical Corp
Karyo Biologics LLC
Karyopharm Therapeutics Inc
KeyMed Biosciences Inc
Keythera Pharmaceuticals Co Ltd
Kintor Pharmaceutical Ltd
Kirilys Therapeutics Inc
KLUS Pharma Inc
Komipharm International Co Ltd
Kringle Pharma Inc
Kronos Bio Inc
Kupffer Biotherapeutics Inc
Kymab Ltd
Kyowa Kirin Co Ltd
L&L Biopharma Co Ltd
Laekna Therapeutics Shanghai Co Ltd
LaNova Medicines Ltd
LATITUDE Pharmaceuticals Inc
Lead Discovery Center GmbH
Leap Therapeutics Inc
Legend Biotech Corp
LegoChem Biosciences Inc
Lepu Biopharma Co Ltd
Les Laboratoires Servier SAS
Leukocare AG
Liangjiang Medicine Co Ltd
Liminatus Pharma LLC
Lindis Biotech GmbH
LintonPharm Co Ltd
Lion TCR Pte Ltd
LipoMedix Pharmaceutical Inc
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Lycera Corp
Lyvgen Biopharma Ltd
Mabpharm Ltd
MacroGenics Inc
Maxinovel Pharmaceuticals
MaxiVAX SA
MBQ Pharma Inc
Mecox Cure Med Co Ltd
MedAbome Inc
Medicenna Therapeutics Corp
Meditope Biosciences Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Merus NV
Metagone Biotech Inc
Metis Precision Medicine
Midissia Therapeutics Inc
Mirati Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech Inc
Morphogenesis Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Mycenax Biotech Inc
Myeloid Therapeutics Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing Tianyi Bioscience Co Ltd
NanoCarrier Co Ltd
NanoMab Technology Ltd
NeuClone Pty Ltd
NewBio Therapeutics Inc
NextCure Inc
NGM Biopharmaceuticals Inc
Nimbus Therapeutics LLC
Nouscom AG
NovaRock Biotherapeutics Inc
Novartis AG
Nurix Therapeutics Inc
OBI Pharma Inc
Ocellaris Pharma Inc
Ona Therapeutics SL
OncoC4 Inc
OncoInsight Co Ltd
Oncolys BioPharma Inc
Oncomatryx Biopharma SL
Onconic Therapeutics Co Ltd
OncoOne Research & Development GmbH
OncoSynergy Inc
OncoTherapy Science Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
OPKO Health Inc
Orano Med LLC
Origincell Technology Group Co Ltd
Otsuka Holdings Co Ltd
Oxford BioTherapeutics Ltd
Palleon Pharmaceuticals Inc
Panbela Therapeutics Inc
Papyrus Therapeutics Inc
Parasol Biotech Co Ltd
Patrys Ltd
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
Pharmapraxis
Philogen SpA
Pieris Pharmaceuticals Inc
Pionyr Immunotherapeutics Inc
PlantForm Corp
Plus Therapeutics Inc
PMV Pharmaceuticals Inc
PNB Vesper Life Science Pvt Ltd
Portage Biotech Inc
Potenza Therapeutics Inc
Precirix NV
Prescient Therapeutics Ltd
Prestige BioPharma Ltd
Promontory Therapeutics Inc
Protheragen Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Quadriga BioSciences Inc
QureBio Ltd
Qurient Co Ltd
Rakuten Medical Inc
Rapa Therapeutics LLC
RAPT Therapeutics Inc
RaQualia Pharma Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Replimune Ltd
Rhizen Pharmaceuticals SA
Roivant Sciences Inc
RS Research
Russian Pharmaceutical Technologies
S.Biomedics Co Ltd
Sanofi
Scancell Holdings Plc
Seagen Inc
SELLAS Life Sciences Group Inc
Seven and Eight Biopharmaceuticals Corp
Shandong Boan Biotechnology Co Ltd
Shandong Golden Brick Biotechnology Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai icell Biotechnology Co Ltd
Shanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shanghai Miracogen Inc
Shanghai PerHum Therapeutics Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Sunstem Biotechnology Co Ltd
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shanghai Yihao Biotechnology Co Ltd
Shanghai Yituo Pharmaceutical Technology Co Ltd
Shanghai Yuyao Biotechnology Ltd
Shenogen Pharma Group Ltd
Shenyang Dongxing Pharmaceutical Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Fapon Biopharma Inc
Shenzhen NeoCura Biotechnology Corp
Shenzhen Salubris Pharmaceuticals Co Ltd
Shijiazhuang No. 4 Pharmaceutical Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sillajen Biotherapeutics
Simcha Therapeutics Inc
Sino Biopharmaceutical Ltd
SinoCelltech Group Ltd
SN BioScience
Sorrento Therapeutics Inc
SOTIO Biotech AS
Sparx Therapeutics Inc
ST Pharm Co Ltd
Statera Biopharma Inc
Stemirna Therapeutics Ltd
Sumitomo Pharma Co Ltd
Suntec Medical (Taiwan) Inc
Surface Oncology Inc
Suzhou Maximum Bio-tech Co Ltd
Suzhou Zanrong Pharmaceutical Technology Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Suzhou Zerun New Drug Research and Development Co Ltd
Symphogen A/S
SynCore Biotechnology Co Ltd
SynOx Therapeutics Ltd
Systimmune Inc
T-Cure Bioscience Inc
Tachyon Therapeutics Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Takis Srl
TargImmune Therapeutics AG
Tarveda Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
TCRx Therapeutics Co Ltd
Teclison Ltd
Tempest Therapeutics Inc
Tessa Therapeutics Ltd
Tonix Pharmaceuticals Holding Corp
Toray Industries Inc
TOT Biopharm Co Ltd
Totus Medicines Inc
Transcenta Holding Ltd
TransThera Sciences (Nanjing) Inc
Treos Bio Ltd
Trio Medicines Ltd
Trishula Therapeutics Inc
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
Turnstone Biologics Inc
Tvardi Therapeutics Inc
Tyg Oncology Ltd
UCB SA
United BioPharma Inc
United Immunity Co Ltd
VacV Biotherapeutics Ltd
Vaxon Biotech
Vedanta Biosciences Inc
Venus Remedies Ltd
Viracta Therapeutics Inc
VM Discovery Inc
Wellington Zhaotai Therapies Ltd
Wuhan YZY Biopharma Co Ltd
Xcovery Holding Co LLC
Xencor Inc
Xiangxue Life Sciences
XuanZhu Biological Technology Co Ltd
Zai Lab Ltd
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang Doer Biologics Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Jianfeng Group Company Ltd
Zhejiang Landun Pharmaceutical Co Ltd
Zhuhai Beihai Biotech Co Ltd
Zymeworks Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Gastric Cancer pipeline drugs market?
Some of the targets of the Gastric Cancer pipeline drugs market are Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1, Cells Expressing Claudin 18, Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Tubulin, Hepatocyte Growth Factor Receptor, CD3, Epidermal Growth Factor Receptor, Claudin 18, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2 among others.
-
What are the mechanisms of action of the Gastric Cancer pipeline drugs market?
The key mechanism of action of the Gastric Cancer pipeline drugs market are Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Claudin 18, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, CD3 Agonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor, Claudin 18 Inhibitor, Hepatocyte Growth Factor Receptor Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, and Fibroblast Growth Factor Receptor 2 Inhibitor among others.
-
What are the routes of administration in the Gastric Cancer pipeline drugs market?
The routes of administration in the Gastric Cancer pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intravenous drip, intratumor, intraperitoneal, intravesical, intramuscular, intradermal, and intralesional among others.
-
What are the molecule types in the Gastric Cancer pipeline drugs market?
The molecule types in the Gastric Cancer pipeline drugs market are Monoclonal Antibody, Small Molecule, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Cell Therapy, Oncolytic Virus, Subunit Vaccine, Biologic, Synthetic Peptide, and Recombinant Protein among others.
-
Which are the leading companies in the Gastric Cancer pipeline drugs market?
Some of the leading companies in the Gastric Cancer pipeline drugs market are Bristol-Myers Squibb Co, Merck & Co Inc, CSPC Pharmaceutical Group Ltd, Incyte Corp, Shanghai Henlius Biotech Inc, Daiichi Sankyo Co Ltd, Innovent Biologics Inc, Jiangsu Hengrui Medicine Co Ltd, Pfizer Inc, Seagen Inc, Akeso Inc, Alphamab Oncology, and AstraZeneca Plc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Oncology reports